Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vest And Scarf Made From Spider Silk (Not KBLB)
http://www.popsci.com/article/science/vest-and-scarf-made-spider-silk?dom=PSC&loc=topstories&con=vest-and-scarf-made-from-spider-silk
This silk scarf and vest have a nice drape and pretty color, but that's not why everyone here at Popular Science covets them. No, we're wishing they were ours because they're made of super-strong, transgenic spider silk. Functional and good-looking! Our favorite.
The clothes were woven from silk produced by silkworms with a spider gene engineered into them. A mix of spider and silkworm proteins actually emerges from the spinners in the silkworms' mouths. The resulting hybrid material is made up of less than 1 percent spider proteins, yet it's 53 percent tougher than regular silk, according to the research team, five scientists from Japan's National Institute of Agrobiological Sciences and Shinshu University.
Scientists have long known spider-silk proteins are exceptionally strong. Dragline silk, the stuff spiders use to make the spokes of their webs and to dangle creepily from ceilings, is five times stronger than an equal-sized thread of steel would be. Researchers have thought about using spider silk for everything from surgical thread to bulletproof vests. There's no reason to make a cute scarf from spider silk, of course, but the Japanese team members wanted to demonstrate they could harvest their product and feed it into the same machines silk factories use.
Why not get the silk directly from spiders, instead of it putting it through a silkworm first? Spiders don't make a lot of silk at once and they're cannibalistic, so it's hard to maintain a spider farm. Silkworms, on the other hand, have been domesticated over thousands of years. They produce voluminous silk cocoons and they're easy to raise indoors. A silkworm that makes spider proteins could be a gentle little biological silk factory, spinning out a super-strong product.
In recent years, a number of labs have created genetically engineered silkworms that spin part-spider silk. However, this is the first time we've seen anybody produce and harvest enough of the material to weave it into something wearable.
In this research, scientists made copies of the genetic code for one dragline protein from Araneus ventricosus spiders. The researchers inserted the copies into the DNA of Japanese silkworms. They performed genetic tests on their worms to show the caterpillars truly did have spider genes and they performed strength tests on the raw silk.
Eventually, they made enough engineered silkworms that they were ready to kill the worms in their cocoons, harvest the silk, dye the silk threads, and knit the threads into cloth, just like silk factories do.
The researchers are now planning to try to raise their genetically engineered silkworms at commercial farms, the Japan Times reports. They published their scientific work last week, in the journal PLOS One.
Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
Webcasts Available Through Cellectar Corporate Website
MADISON, Wis., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that Dr. Simon Pedder, chief executive officer, will be presenting a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference being held September 8 - 10, 2014 at the New York Palace Hotel in New York and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore at Wynn in Las Vegas.
Event: Rodman & Renshaw 16th Annual Global Investment Conference
Date: Tuesday, September 9, 2014
Time: 1:40 p.m. Eastern Time
Location: New York Palace Hotel, New York, NY
Event: Aegis Capital Healthcare and Technology Conference
Date: Thursday, September 11, 2014
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Encore at Wynn, Las Vegas, NV
Live audio webcasts of both the Rodman & Renshaw presentation and the Aegis Capital presentation will be available on the Company's website on the Investor Relations Events page at http://investor.cellectar.com/events.cfm. The webcast replays will be available approximately two hours after each presentation ends and will be accessible for 90 days.
Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
MADISON, Wis., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells.
I-131-CLR1404 is radiotherapeutic comprised of a proprietary phospholipid ether (PLE) analog, acting as a cancer-targeted delivery and retention vehicle, covalently labeled with Iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer types. Because Cellectar's PLE platform has been shown to reliably and universally accumulate in malignant cancer cells, and the therapeutic properties of the Iodine-131 isotope are well known, I-131-CLR1404 is engineered to combine an intracellular radiation mechanism of destroying cancer cells, including cancer stem cells, through targeted delivery specific to malignant tissue that spares critical normal tissues from consequential radiation dose.
Cellectar plans to initiate a Phase I/II, proof-of-concept trial during the fourth quarter 2014 in approximately 20 patients with relapsed or refractory multiple myeloma that have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. The primary objective of the study will be to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone. In addition, the trial will seek to identify the recommended dose for future pivotal trials and determine therapeutic activity of I-131-CLR1404 in this patient population as measured by overall response rate, time to progression and duration of response.
"This trial affords us an opportunity to both assess the safety of I-131-CLR1404 in patients with multiple myeloma, but also to obtain near-term proof-of-concept data characterizing the activity of I-131-CLR1404 in this difficult-to-treat patient population," commented Dr. Simon Pedder, president and chief executive officer. "Having initiated a Phase II diagnostic imaging trial of our lead compound, I-124-CLR1404, in glioblastoma earlier in the year, we are pleased to now have this opportunity to initiate a second, company-sponsored clinical trial with the potential to showcase the therapeutic applications of our targeted delivery platform."
Near Term Events:
Shareholder Re-Vote on Increasing the Share Count - 2014?
Chemistry Perfected - 2014/2015?
Bleached Waveguide Modulator Demonstration (per ASM slides) - 2014
Slot Waveguide Modulator Demonstration (per ASM slides) - 2014
Spatial Light Modulator Demonstration (per ASM slides) - 2015
100 GB/s Hybrid Modulator Demonstration (per ASM slides) - 2015
Joint Venture/Partnership/Acquisiton - 2015??? (guess)
Am I missing anything else?
Thanks for the updates. Is this available for replay yet?
Yea that's kind of how I felt about what I did hear, not that it was bad news by any means. Guess we have still have a ways to go...
Wasn't able to listen to the whole thing...anything notable/near term worth mentioning?
Wow I wonder if they are direct competitors. After the ASM tomorrow I would like to hear Management's thoughts on Acacia's tech...
Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
MADISON, Wis., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.
Event Details:
Interested investors may participate in the conference call by dialing 888-646-8293 (domestic) or 973-453-3065 (international). A replay will be available for one week following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering conference ID 90511388 when prompted. Participants may also access both the live and archived webcast of the conference call on the investor relations section of Cellectar's web site, www.cellectar.com.
To Ask Questions:
Following prepared remarks and time permitting, management will provide an opportunity for participants dialed into to the live teleconference to ask questions. Investors may also e-mail their questions to ir@cellectar.com. E-mail questions will be accepted until 12:00 noon ET on Wednesday, August 20, 2014.
Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering
http://finance.yahoo.com/news/cellectar-biosciences-announces-pricing-12-233952347.html
Cellectar Biosciences, Inc. (CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today the pricing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants are exercisable immediately and expire five years from their date of issuance. The warrants will have an exercise price of $4.68 per share and will trade on the NASDAQ Capital Market under the symbol "CLRBW."
The gross proceeds to Cellectar from this offering are expected to be approximately $12,500,000 in new cash proceeds before deducting underwriting discounts and other offering expenses payable by Cellectar. Cellectar has granted the underwriter a 45-day option to purchase up to an additional 500,000 shares of common stock and/or an additional 500,000 warrants to cover over-allotments, if any. The offering is expected to close on or about August 20, 2014, subject to customary closing conditions.
Certain of Cellectar's directors and officers have expressed an interest in participating in the public offering of common stock and warrants.
In Connection with its listing on The NASDAQ Capital Market, Cellectar's common stock will cease trading on the OTCQX Market.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
In conjunction with the underwritten offering, the holders of Cellectar's outstanding convertible debentures tendered an aggregate of $4,000,000 in principal amount, plus approximately $172,000 of accrued interest, of such debentures to purchase approximately 1,110,000 of the shares of common stock offered, plus the same number of warrants. Including tender of all outstanding convertible debentures, the company is offering a total of approximately 4,400,000 common shares and an equal number of warrants.
Interesting article today on the news page.
"Two other quantum dot makers plan to shift their listings to larger exchanges, their CEOs told Reuters. Nanoco Group Plc will move to the London Stock Exchange from the bourse's AIM, and San Marcos, Texas-based Quantum Materials Corp will go to the New York Stock Exchange or Nasdaq from over the counter."
http://finance.yahoo.com/news/sharp-focus-quantum-dot-makers-180431178.html
Do they plan to do a reverse split soon to accomplish this (move exchanges to NYSE or NASDAQ)?
Also, what is the difference between Nanoco andd QTMM's technology?
TIA!
When our correction comes and the market finally starts to value the CTIX pipeline appropriately, it is going to be fun to watch the SP move...is it Q4 yet??? ;)
I agree, they have potential to own a higher percentage of shares than 38% which may (likely) happen in time as the pipeline fully develops/comes to fruition and they decide to exercise/convert warrants/options/class B shares as desired.
I was not criticizing, I am fully on board with everything management does and the fact that they own 38% of the class A shares tells me that their interests are perfectly aligned with that of shareholders. My only intention was to clear up the number of shares currently owned by management, as it is different than the potentially owned in the future number being reported here.
It seemed misleading to me, to say that management owns 85% of the shares because currently that is incorrect. Did not mean any offense.
Thanks for following up. Just to clarify, I am long CTIX so please don't mistake my intentions. I've seen random numbers posted before without any support and I like to keep things factual when there are facts to draw from. It seems we are both correct on this.
The numbers I reported are solely for currently owned class A shares and do not include additional options, or class B "super shares" which I believe your numbers do account for which is why your numbers seemed high to me, because those options and class B shares have not all vested or been implemented (in the case of class B super shares) yet.
Looking forward to much more positive news in the near term..
GLTA
I checked the last 10Q on insider ownership, think your numbers were a bit off. Still nothing to slouch at though by any means:
"At March 31, 2014, our directors and executive officers own or control approximately 38% of our outstanding voting power of Class A Common Stock. "
According to the 10Q CLRB only has enough cash to last them the rest of the month?
Wonder when they will announce a private placement...
After today I believe it will be 8 trading days. Think it started closing above $1 on Thursday, 7/31 although I could be wrong.
Interesting thought jok.
With human trials nearing Phase 3 it probably doesn't make sense right now to divert attention but that could be a nice additional income stream down the line. Wonder what it costs to bring a drug into the veterinary market? Have to imagine the hurdles/costs are significantly lower, especially if you were to just partner up on it. Might be worth sending them an email about it though.
UK-based startup Optalysys is moving ahead to deliver exascale levels of processing power on a standard-sized desktop computer within the next few years...The company itself announced on August 1 that it is "only months away from launching a prototype optical processor with the potential to deliver exascale levels of processing power on a standard-sized desktop computer." The company will demo its prototype, which meets NASA Technology Readiness Level 4, in January next year.
http://phys.org/news/2014-08-optalysys-prototype-optical-processor.html
So 3-4 months until the phase 3 can start for Prurisol. I imagine that the same timeframe will apply once Brilacidin completes phase 2 as well so possibly sometime in January 2015 for the start of Prurisol phase 3 and March 2015 for the start of Brilacidin Phase 3? Either way, the end of both 2014 and 2015 are looking to be very exciting times!
Which of those drugs are we looking to partner with someone for the phase 3 trials?
Does anyone know if they plan to find a partner for Prurisol PH II/III? Or will they go it alone?
All the shares the Lauro have picked up have been as a result of his work on the Operations Committee. Per the form 4:
Explanation of Responses:
( 1) Acquired directly from the issuer in connection with Operations Committee work.
" FDA approves The Medicines Co's acute skin infection drug
The U.S. Food and Drug Administration approved The Medicines Co's single-dose intravenous drug to treat acute bacterial skin infections, the agency's third approval for the same condition this year.
.....
The antibiotic received an expedited review by the FDA and was designated a qualified infectious disease product, qualifying it for an extra five years of marketing exclusivity.
Jefferies & Co analyst Biren Amin told Reuters he expects Orbactiv to be launched in the fourth quarter and estimated peak U.S. sales of $150 million by 2021. "
(http://news.yahoo.com/fda-approves-medicines-cos-acute-skin-infection-drug-222825203--finance.html)
Found that interesting. Expedited review/approval, single-dose, and only $150 million peak sales expected???
EDIT: OOPS, looks like I was late to report on this...
How many days does the SP have to be over $1 before Lightwave can tap LPC? Can someone please refresh my memory? TIA
I'm inclined to think that it is still related to raising capital via LPC. If they want to acquire another company, they will need cash, and probably more than the $3 million that was raised in the PP.
I hope I am wrong and that it is substantial news about materials/working device testing results. Although it wouldn't be terrible if they acquired a company and started generating revenue and had an existing list of customers ready to purchase from LWLG's forthcoming product lines.
Wonder if movement on that was dependent on the newer, temperature stable formulation of Brilacidin that they PR'd recently..
"Our technical team is currently putting together individual product timelines along with market sizes and detailed competitive comparisons that we intend to share with you when completed."
My guess is that the above is what we will receive at the Shareholder Meeting a month from now.
Lots of time frames and milestones slated for late summer and/or early fall. Sounds like we are entering an exciting time! Might consider buying back some of the shares I unloaded late last year...
"Novel regulator of a protein inactive in over 50 percent of human tumors" 7/21/2014
They are discussing P53
http://medicalxpress.com/news/2014-07-protein-inactive-percent-human-tumors.html
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona have discovered the interaction between HERC2 proteins with another protein called p53 that is inactivated in more than half of human tumors.
The study results were published in the Journal of Biological Chemistry.
Regulation of the activity of p53 by HERC2
The team of José Luis Rosa, at the growth factors and cell differentiation research group at IDIBELL studies the molecular mechanisms of HERC family proteins. These proteins are ubiquitin ligases that regulate the function of other proteins. "In recent years," explained Rosa "it has been shown that alterations in HERC family proteins are associated with various pathologies including ataxia, mental retardation and cancer."
"Under physiological conditions, the role of the p53 protein is to protect from uncontrolled cell growth. Thus, mutations or other mechanisms to inhibit the function of p53, are associated with increased cell proliferation" as the researcher says "as a tumor is formed by uncontrolled cell growth, it is not surprising that an important step in tumor progression would be the inactivation of p53."
P53 protein regulates the expression of genes involved in important cellular processes such as cell proliferation. Its activity is dependent on acquiring a structure of four associated molecules called tetramer. Researchers have found that HERC2 is necessary for the formation of the tetramer of p53 (termed oligomerization process) and thus HERC2 regulates p53 activity under physiological conditions.
HERC2 and cancer
The study suggests that mutations in HERC2 also may be associated with cancer in humans. "In the laboratory we have observed that without HERC2 cells increases proliferation. It's the same effect as if they inactivated p53" says Rosa.
Steve, if you read further down the Form 4 for Lauro you will see this:
Explanation of Responses:
1. Acquired directly from the issuer in connection with Operations Committee work
Cubist is located only a couple towns away from CTIX in Lexington, MA which is only a distance of 25 miles. Based on proximity to Beverly, MA where CTIX is located I'd have to imagine that Leo has at least had or will have one meeting with Cubist at some point. Don't know if they'd be a likely partner contender if the data is good but it doesn't seem out of the realm of possibilities.
Wonder if that PR counts as the "update" they will provide before the shareholder meeting. It at least fits the bill for a token monthly PR for July.
Wow, still can't get it over a dollar even with the heavy volume
Does this indicate that the offering is now closed?
Thanks craig I appreciate the follow up response. Only a few months away from some milestones it seems.
September for the start of the IDE or the start of the clinical trial...Or do the two go hand in hand?
Hoping it is an upcoming PR and not an attempt to make the private placement look more attractive at .75
I understand that it is a controversial point of view. Perhaps once closer to FDA acceptance of the hemopurifier would be a better time. However, I really don't know how they would be able to uplist and raise substantial capital for manufacturing ramp up without a RS though. And without uplisting they won't be able to attract reputable institutional buyers as far as I know.
I am also waiting on the sidelines for them to get further along before I invest so I understand your concern as a current investor.
I really think Aethlon should consider a reverse split once they get the trial completed and the results published. They need to get uplisted and make this a more appealing stock for Institutional buyers.
Can someone refresh my memory on when the trial is expected to begin?
From what I understand, the agreement with Fraunhofer is for 3 months and they are supposed to hit certain milestones. If Natcore is happy with the work then there is the option to extend the agreement/work for another 9 months.